56 Delhi Road
Suite 3.3 North Ryde
Sydney, NSW 2113
Australia
61 2 9805 0488
https://www.biotron.com.au
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Executive Director | 387.43k | N/A | N/A |
Mr. Peter James Nightingale B.Econ, CA | Company Secretary | 120k | N/A | 1957 |
Dr. Stephen L. Becker M.D. | Chief Medical Officer | N/A | N/A | N/A |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.